生物医药专刊

免疫检查点抑制剂引起的心血管动脉粥样硬化事件及中西医防治策略

展开
  • 北京中医药大学东直门医院,中医内科学教育部和北京市重点实验室,北京 100700

收稿日期: 2021-11-22

  网络出版日期: 2022-05-05

Cardiovascular atherosclerotic events caused by immune checkpoint inhibitors and prevention and treatment strategies of traditional Chinese and western medicine

Expand
  • Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

Received date: 2021-11-22

  Online published: 2022-05-05

摘要

随着免疫检查点抑制剂在肿瘤治疗中的广泛应用,癌症患者的生存期得到有效延长,但随之而来的心脏毒性问题日渐凸显,其中冠状动脉疾病、心肌梗死和缺血性卒中等动脉粥样硬化性血管事件因起病急、预后差而引起学者的关注。文章系统阐述了免疫检查点抑制剂治疗引起的心血管动脉粥样硬化事件,产生这种心脏毒性的风险因素及风险评估,以及潜在的发生机制和中西医防治策略。

本文引用格式

刘文静, 张晓雨, 韩松洁, 代倩倩, 商洪才 . 免疫检查点抑制剂引起的心血管动脉粥样硬化事件及中西医防治策略[J]. 自然杂志, 2022 , 44(2) : 117 -125 . DOI: 10.3969/j.issn.0253-9608.2022.02.006

Abstract

The survival time of cancer patients is effectively prolonged with the widespread application of immune checkpoint inhibitors in tumor treatment, and subsequently, the cardiotoxicity problems including coronary artery disease, myocardial infarction, and ischemic stroke became increasingly prominent which arouse the attention on cardiovascular atherosclerotic events of scholars
because of the urgent appearance and poor prognosis. The article systematically described the cardiovascular atherosclerotic events caused by immune checkpoint inhibitor therapy, the risk factors and risk assessment of this cardiotoxicity, the underlying mechanism, and the prevention and treatment strategies of Chinese and western medicine.
文章导航

/